Table 1: Drug-induced immune hemolytic anemia secondary to perioperative prophylactic use of cefotetan in obstetrics and gynecology.
Case |
Publication |
Procedure |
Initial postoperative Hgb or HCT |
Cefotetan-induced immune hemolytic anemia |
||||||
Postoperative time to diagnosis (days) |
Hgb or HCT |
Reticulocyte count (%) |
Bilirubin, Total (mg/dL) |
Bilirubin, Indirect (mg/dL) |
Lactate dihydrogen-ase (U/L) |
Haptoglobin (mg/dL) |
||||
1 |
Shariatmadar [5] |
Cesarean |
--- |
2 weeks |
14.80% |
15 |
3.5 |
--- |
750 |
Normal |
2 |
Naylor [6] |
Cesarean |
29% |
13 |
11% |
6.8 |
2.5 |
2.3 |
--- |
< 6 |
3 |
Cesarean |
35% |
9 |
23% |
9.1 |
1.9 |
--- |
338 |
7 |
|
4 |
Cesarean |
--- |
9 |
8% |
11.1 |
5.4 |
4.8 |
448 |
--- |
|
5 |
Garratty [7] |
Enterocele repair |
11.6 g/dL |
9 |
6.8 g/dL |
--- |
--- |
6.1 |
--- |
< 5 |
6 |
Cesarean |
7.5 g/dL |
10 |
3.5 g/dL |
30.6 |
--- |
5.4 |
607 |
< 50 |
|
7 |
Cesarean |
9.9 g/dL |
12 |
4.0 g/dL |
--- |
--- |
2.2 |
1987 |
--- |
|
8 |
Cesarean |
--- |
14 |
6.1 g/dL |
--- |
--- |
--- |
--- |
--- |
|
9 |
Cesarean |
9.6 g/dL |
9 |
2.6 g/dL |
--- |
5.3 |
--- |
1849 |
--- |
|
10 |
Cesarean |
--- |
9 |
3.4 g/dL |
--- |
27.6 |
--- |
2150 |
< 6 |
|
11 |
Cesarean |
10.8 g/dL |
9 |
3.7 g/dL |
5.1 |
5 |
--- |
2967 |
--- |
|
12 |
Curettage |
--- |
14 |
7.6 g/dL |
2.5 |
--- |
3.1 |
233 |
< 6 |
|
13 |
Mohammed [8] |
Colporrhaphy |
11 g/dL, 32% |
6 |
4.8 g/dL, 12.8% |
3.2 |
5.2 |
--- |
1170 |
--- |
Hgb: Hemoglobin; HCT: Hematocrit